Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13783796 | 1.00 | FUCA1 (0.60) | FUCA1KDM1ASIGMAR1DRD2DRD3 | |
| SCHEMBL1021817 | 1.00 | FUCA1 (0.60) | FUCA1KDM1ASIGMAR1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL15751188 | 0.98 | FUCA1 (0.58) | FUCA1KDM1ASIGMAR1DRD2DRD3 | |
| SCHEMBL5242542 | 0.91 | FUCA1 (0.64) | FUCA1KDM1ASIGMAR1DRD2DRD3 | |
| SCHEMBL23939426 | 0.88 | FUCA1 (0.68) | FUCA1KDM1ASIGMAR1DRD2DRD3 | |
| SCHEMBL22796181 | 0.88 | ACHE (0.58) | FUCA1KDM1ASIGMAR1DRD2DRD3 | |
| SCHEMBL4090277 | 0.88 | KDM1A (0.54) | FUCA1KDM1ASIGMAR1DRD2DRD3 | |
| SCHEMBL20858838 | 0.88 | FUCA1 (0.53) | FUCA1KDM1ASIGMAR1DRD2DRD3 | |
| SCHEMBL21561563 | 0.88 | FUCA1 (0.68) | FUCA1KDM1ASIGMAR1DRD2DRD3 | |
| SCHEMBL13291911 | 0.88 | ACHE (0.58) | FUCA1KDM1ASIGMAR1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | FUCA1 3406/4885KDM1A 525/4885SIGMAR1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.